Skip to content
Baltimore News Journal – Lifestyle
Author:
Boehringer Ingelheim Limited
Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
October 1, 2026
Boehringer Ingelheim investments into sustainability-related programs and health partnerships to reach EUR 500 million
September 29, 2026
Boehringer Ingelheim and AWARE launch new Stop Rabies project in Zimbabwe to help protect dogs and communities
September 23, 2026
Boehringer Ingelheim launches PED Essentials, an online learning resource that gives patients a stronger voice
September 17, 2026
Boehringer Ingelheim launches SCOVELLA® in Great Britain, the first approved therapy for insulin dysregulation in horses, a main cause of laminitis
September 1, 2026
Boehringer Ingelheim Celebrates Grand Opening of New U.S. Animal Health Headquarters in Johns Creek, Georgia
August 31, 2026
Boehringer Ingelheim expands equine health pipeline with acquisition of Evax AG
August 11, 2026
Boehringer Ingelheim Spotlights Next Generation of Veterinary Researchers
August 10, 2026
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
July 16, 2026
Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
July 15, 2026
1
2
3
Next Page
→